Clearmind Medicine, Inc. (CMND)
4.53
-0.09
(-1.95%)
USD |
NASDAQ |
Nov 13, 16:00
4.465
-0.06
(-1.43%)
After-Hours: 19:59
Clearmind Medicine Enterprise Value : -12.92M for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | -12.92M |
| November 12, 2026 | -12.89M |
| November 11, 2026 | -12.80M |
| November 10, 2026 | -12.77M |
| November 09, 2026 | -12.66M |
| November 06, 2026 | -12.63M |
| November 05, 2026 | -12.56M |
| November 04, 2026 | -12.54M |
| November 03, 2026 | -12.54M |
| November 02, 2026 | -12.48M |
| October 30, 2026 | -12.46M |
| October 29, 2026 | -12.56M |
| October 28, 2026 | -12.51M |
| October 27, 2026 | -12.53M |
| October 26, 2026 | -12.49M |
| October 23, 2026 | -12.56M |
| October 22, 2026 | -12.52M |
| October 21, 2026 | -12.54M |
| October 20, 2026 | -12.49M |
| October 19, 2026 | -12.52M |
| October 16, 2026 | -12.45M |
| October 15, 2026 | -12.41M |
| October 14, 2026 | -12.44M |
| October 13, 2026 | -12.46M |
| October 12, 2026 | -12.38M |
| Date | Value |
|---|---|
| October 09, 2026 | -12.37M |
| October 08, 2026 | -12.36M |
| October 07, 2026 | -12.36M |
| October 06, 2026 | -12.56M |
| October 05, 2026 | -12.52M |
| October 02, 2026 | -12.60M |
| October 01, 2026 | -12.60M |
| September 30, 2026 | -12.40M |
| September 29, 2026 | -12.39M |
| September 28, 2026 | -12.44M |
| September 25, 2026 | -12.41M |
| September 24, 2026 | -12.39M |
| September 23, 2026 | -12.31M |
| September 22, 2026 | -12.46M |
| September 21, 2026 | -12.43M |
| September 18, 2026 | -12.42M |
| September 17, 2026 | -12.29M |
| September 16, 2026 | -12.40M |
| September 15, 2026 | -12.28M |
| September 14, 2026 | -12.11M |
| September 11, 2026 | -12.06M |
| September 10, 2026 | -12.02M |
| September 09, 2026 | -11.86M |
| September 08, 2026 | -11.92M |
| September 04, 2026 | -11.64M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| NervGen Pharma Corp. | 138.88M |
| Milestone Pharmaceuticals, Inc. | 63.15M |
| Appili Therapeutics, Inc. | 9.586M |
| Lexaria Bioscience Corp. | 3.413M |
| Target Group, Inc. (Canada) | 11.72M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.9073M |
| Total Expenses (Quarterly) | 0.9073M |
| EPS Diluted (Quarterly) | -4.588 |
| Earnings Yield | -15.57K% |
| Normalized Earnings Yield | -21482.36 |